SPR Therapeutics Named a Top Workplace
26 juin 2022 11h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer. The award is based on employee feedback gathered...
SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-altering Pain
12 mai 2022 09h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, May 12, 2022 (GLOBE NEWSWIRE) -- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System....
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
06 mai 2022 09h24 HE
|
SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
15 mars 2022 10h31 HE
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
18 nov. 2021 12h32 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
19 oct. 2021 12h22 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System
18 oct. 2021 09h17 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has...
SPR Therapeutics CEO Maria Bennett Selected as Winner of EY Entrepreneur of the Year in East Central Region
06 août 2021 10h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, Aug. 06, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce that President, Founder and CEO Maria Bennett has been selected as an Ernst & Young (EY) Entrepreneur Of The...
Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life
12 juil. 2021 08h00 HE
|
SPR Therapeutics, Inc.
CLEVELAND, July 12, 2021 (GLOBE NEWSWIRE) -- In the largest, most rigorous study to date using the SPRINT® PNS System for chronic axial low back pain (LBP), patients that failed to find relief from...
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
26 avr. 2021 09h41 HE
|
SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...